A5044648212- Intraperitoneal and Appendiceal Malignancies
- Nanoparticle-Based Drug Delivery
- Ovarian cancer diagnosis and treatment
- Ultrasound and Hyperthermia Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Appendicitis Diagnosis and Management
- Radiation Therapy and Dosimetry
Amsterdam University Medical Centers
2023-2024
University of Amsterdam
2023-2024
Center for Translational Molecular Medicine
2023
Cancer Center Amsterdam
2023
Introduction In patients with limited peritoneal metastasis (PM) originating from colorectal cancer, cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment option. This combined modality using HIPEC mitomycin C (MMC) for 90 minutes proved to be superior systemic alone, but no benefit of adding CRS alone was shown oxaliplatin-based during 30 minutes. We investigated the impact temperature and duration as relevant...
Introduction Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) aims to treat microscopic disease left after CytoReductive Surgery (CRS). Thermal enhancement depends on the temperatures achieved. Since location of is unknown, a homogeneous treatment required completely eradicate while limiting side effects. To ensure delivery, planning software has been developed. This study compares simulation results with clinical data and evaluates impact nine strategies thermal drug distributions.Methods...
Peritoneal metastases (PMs) from colorectal cancer (CRC) respond poorly to treatment and are associated with unfavorable prognosis. For example, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgery in resectable patients shows limited benefit, novel treatments urgently needed. The majority CRC-PMs represent CMS4 molecular subtype CRC, here we queried vulnerabilities this pharmacogenomic databases identify therapies. This reveals copper ionophore elesclomol...